Key result
Combination therapy with low-dose adriamycin and radiation resulted in partial or complete responses in 62% of patients with soft-tissue sarcomas.
Why the study?
Does combination therapy with low-dose adriamycin and radiation improve tumor response rates in adult patients with advanced malignancies?
Does combination therapy with low-dose adriamycin and radiation improve tumor response rates in adult patients with advanced malignancies?
Combination therapy with low-dose adriamycin and radiation demonstrated a 62% response rate in adult patients with soft-tissue sarcomas, with moderate toxicity.
Should not yet change practice; hypothesis-generating for low-dose adriamycin plus radiation in soft-tissue sarcomas.
Based on reports of synergism between adriamycin and radiation therapy in experimental systems, a trial was initiated testing this combination in 53 adult patients with various advanced malignancies, especially sarcomas. Since studies have suggested as selective sensitization of hypoxic cells when this drug is given prior to radiation, an injection of low-dose adriamycin was given 90 min before radiation. This treatment was repeated every 7 days. The combination was most effective in the 30 patients with soft-tissue sarcomas, with 62% of these patients having partial or complete responses. Responses were less good in patients with gastric adenocarcinoma or with other tumors. The toxicity of the combined treatment was moderate. Further trials of this combination are warranted.
No takes yet. Share an insight, caveat, or question.
Sordillo et al. (1982) studied Advanced malignancies, especially sarcomas (n=53). Adriamycin and radiation therapy was evaluated on Partial or complete responses. Combination therapy with low-dose adriamycin and radiation resulted in partial or complete responses in 62% of patients with soft-tissue sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: